On Monday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened higher 4.69% from the last session, before settling in for the closing price of $241.76. Price fluctuations for ALNY have ranged from $141.98 to $304.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 63.53% over the last five years. Company’s average yearly earnings per share was noted 26.92% at the time writing. With a float of $123.76 million, this company’s outstanding shares have now reached $129.29 million.
The firm has a total of 2230 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.62%, operating margin of -7.87%, and the pretax margin is -16.79%.
Alnylam Pharmaceuticals Inc (ALNY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alnylam Pharmaceuticals Inc is 4.40%, while institutional ownership is 95.50%. The most recent insider transaction that took place on Mar 03 ’25, was worth 465,772. In this transaction CSO & EVP, Head of Research of this company sold 1,911 shares at a rate of $243.73, taking the stock ownership to the 14,345 shares. Before that another transaction happened on Mar 04 ’25, when Company’s CSO & EVP, Head of Research sold 844 for $241.15, making the entire transaction worth $203,532. This insider now owns 13,501 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.92% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Check out the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). In the past quarter, the stock posted a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.93 in the next quarter and is forecasted to reach 1.18 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Analysing the last 5-days average volume posted by the [Alnylam Pharmaceuticals Inc, ALNY], we can find that recorded value of 0.55 million was lower than the volume posted last year of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 66.20%. Additionally, its Average True Range was 9.05.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 32.67%, which indicates a significant decrease from 99.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.40% in the past 14 days, which was higher than the 39.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $254.70, while its 200-day Moving Average is $250.25. Now, the first resistance to watch is $257.29. This is followed by the second major resistance level at $261.48. The third major resistance level sits at $269.65. If the price goes on to break the first support level at $244.93, it is likely to go to the next support level at $236.76. Now, if the price goes above the second support level, the third support stands at $232.57.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are currently 129,457K shares outstanding in the company with a market cap of 32.77 billion. Presently, the company’s annual sales total 2,248 M according to its annual income of -278,160 K. Last quarter, the company’s sales amounted to 593,170 K and its income totaled -83,760 K.
